An interferon-free combination of the protease inhibitor ABT-@ with ritonavir ( ABT-@ / r ) , the nonnucleoside polymerase inhibitor ABT-@ , and ribavirin showed efficacy against the hepatitis C virus ( HCV ) in a pilot study involving patients with HCV genotype @ infection .